[1]
|
Forghieri, F., Luppi, M. and Potenza, L. (2015) Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. Hematology, 20, 618-619. https://doi.org/10.1179/1024533215Z.000000000402
|
[2]
|
中华医学会血液学分会, 中国抗癌协会血液肿瘤专业委员会. 中国成人急性淋巴细胞白血病诊断与治疗专家共识[J]. 中华血液学杂志, 2012, 33(9): 789-792.
|
[3]
|
刘娟, 张闰, 葛峥, 林忠琨, 柳萍, 仇海荣, 李建勇, 等. 217例成人急性淋巴细胞白血病遗传学特征及其临床预后意义的研究[J]. 中华医学遗传学杂志, 2013, 30(2): 1003-9406.
|
[4]
|
Komorowski, L., Fidyt, K., Patkowska, E. and Firczuk, M. (2020) Philadelphia Chromosome-Positive Leukemia in the Lymphoid Lineage—Similarities and Differences with the Myeloid Lineage and Specific Vulnerabilities. International Journal of Molecular Sciences, 2020, 5776. https://doi.org/10.3390/ijms21165776
|
[5]
|
Dalle, I.A., Kantarjian, H.M., Short, N.J., Konopleva, M., Jain, N., et al. (2019) Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia at First Relapse in the Era of Tyrosine Kinase Inhibitors. American Journal of Hematology, 94, 1388-1395. https://doi.org/10.1002/ajh.25648
|
[6]
|
Tanguy-Schmidt, A., Rousselot, P., et al. (2013) Long-Term Follow-Up of the Imatinib GRAAPH-2003 Study in Newly Diagnosed Patients with de Novo Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A GRAALL Study. Biology of Blood and Marrow Transplantation, 19, 150-155. https://doi.org/10.1016/j.bbmt.2012.08.021
|
[7]
|
Lickliter, J.D., TayoIor, K., Szer, J., et al. (2015) An Imatinib-Only Window Followed by Imatinib and Chemotherapy for Philadelphia Chromosome-Positive Acute Leukemia: Long-Term Results of the CMLALL1 Trial. Leukemia & Lymphoma, 56, 630-638. https://doi.org/10.3109/10428194.2014.925547
|
[8]
|
Fielding, A.K., Rowe, J.M., Buck, G., Foroni, L., Gerrard, G., et al. (2014) UKALLXII/ECOG2993: Addition of Imatinib to a Standard Treatment Regimen Enhances Long-Term Outcomes in Philadelphia Positive Acute Lymphoblastic Leukemia. Blood, 123, 843-850. https://doi.org/10.1182/blood-2013-09-529008
|
[9]
|
Daver, N., Thomas, D., Ravandi, F., et al. (2015) Final Report of a Phase II Study of Imatinib Mesylate with Hyper-CVAD for the Front-Line Treatment of Adult Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. Haematologica, 100, 653-661. https://doi.org/10.3324/haematol.2014.118588
|
[10]
|
Mizuta, S., Matsuo, K., Nishiwaki, S., Imai, K., et al. (2014) Pretransplant Administration of Imatinib for Allo-HSCT in Patients with BCR-ABL-Positive Acute Lymphoblastic Leukemia. Blood, 123, 2325-2332.
https://doi.org/10.1182/blood-2013-11-538728
|
[11]
|
Nishiwaki, S., Miyamura, K., Kato, C., Terakura, S., et al. (2010) Impact of Post-Transplant Imatinib Administration on Philadelphia Chromosome-Positive Acute Lymphoblastic Leukaemia. Anticancer Research, 30, 2415-2418.
|
[12]
|
Chen, H., Liu, K.Y., Xu, L.P., Liu, D.H., Chen, Y.H., et al. (2012) Administration of Imatinib after Allogeneic Hematopoietic Stem Cell Transplantation May Improve Disease-Free Survival for Patients with Philadelphia Chromosome-Positive Acute Lymphobla Stic Leukemia. Journal of Hematology & Oncology, 5, Article No. 29.
https://doi.org/10.1186/1756-8722-5-29
|
[13]
|
Lim, S.-N., Joo, Y.-D., Lee, K.-H., Kim, D.-Y., Lee, J.-H., et al. (2015) Long-Term Follow-Up of Imatinib plus Combination Chemotherapy in Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. American Journal of Hematology, 90, 1013-1020. https://doi.org/10.1002/ajh.24137
|
[14]
|
Akahoshi, Y., Nishiwaki, S., Mizuta, S., Ohashi, K., et al. (2019) Tyrosine Kinase Inhibitor Prophylaxis after Transplant for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. Cancer Science, 110, No. 10.
https://doi.org/10.1111/cas.14167
|
[15]
|
Pavlovsky, C., Chan, O., Talati, C. and Pinilla-Ibarz, J. (2019) Ponatinib in the Treatment of Chronic Myeloid Leukemia and Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia. Future Oncology, 15, 257-269.
https://doi.org/10.2217/fon-2018-0371
|